Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study
Show others and affiliations
2017 (English)In: BMC Medicine, E-ISSN 1741-7015, Vol. 72, no 15Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Leakage of bacterial products across the gut barrier may play a role in liver diseases which often precede the development of liver cancer. However, human studies, particularly from prospective settings, are lacking.

METHODS: We used a case-control study design nested within a large prospective cohort to assess the association between circulating levels of anti-lipopolysaccharide (LPS) and anti-flagellin immunoglobulin A (IgA) and G (IgG) (reflecting long-term exposures to LPS and flagellin, respectively) and risk of hepatocellular carcinoma. A total of 139 men and women diagnosed with hepatocellular carcinoma between 1992 and 2010 were matched to 139 control subjects. Multivariable rate ratios (RRs), including adjustment for potential confounders, hepatitis B/C positivity, and degree of liver dysfunction, were calculated with conditional logistic regression.

RESULTS:  = 0.021). This finding did not vary substantially by time from enrollment to diagnosis, and did not change after adjustment for chronic infection with hepatitis B and C viruses.

CONCLUSIONS: These novel findings, based on exposures up to several years prior to diagnosis, support a role for gut-derived bacterial products in hepatocellular carcinoma development. Further study into the role of gut barrier failure and exposure to bacterial products in liver diseases is warranted.

Place, publisher, year, edition, pages
BioMed Central, 2017. Vol. 72, no 15
Keywords [en]
Endotoxins, Flagellin, Hepatocellular carcinoma, Lipopolysaccharide, Prospective studies
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:umu:diva-146516DOI: 10.1186/s12916-017-0830-8ISI: 000398034900001PubMedID: 28372583OAI: oai:DiVA.org:umu-146516DiVA, id: diva2:1196928
Funder
Swedish Cancer SocietyRegion SkåneVästerbotten County CouncilAvailable from: 2018-04-11 Created: 2018-04-11 Last updated: 2022-05-10Bibliographically approved

Open Access in DiVA

fulltext(2091 kB)183 downloads
File information
File name FULLTEXT01.pdfFile size 2091 kBChecksum SHA-512
a55c94db57c4ded1c9e7b596160107cc4eaf7dab465b814c357390db171d75bd39aa6404b2ad2effa8d055b6b796665152875efa21979ed54d65bf0149004f36
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Hemmingsson, OskarWerner, Mårten

Search in DiVA

By author/editor
Hemmingsson, OskarWerner, Mårten
In the same journal
BMC Medicine
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 183 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 280 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf